{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:38:55Z","timestamp":1768833535191,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30EY003039"],"award-info":[{"award-number":["P30EY003039"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY025756"],"award-info":[{"award-number":["R01EY025756"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Whitecoat adherence refers to improved medication adherence in the days surrounding clinic visits. This may lead to clinical measures that are not representative of those outside of clinical encounters. In glaucoma, whitecoat adherence to prescribed hypotensive therapy may lead to intraocular pressure readings within the target range, which may impact clinical decision-making. We aimed to quantify and identify factors associated with whitecoat adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort study, patients with primary open-angle glaucoma were selected from an ongoing longitudinal NIH-funded study if they used hypotensive eyedrops, had a clinic visit during the parent study, and had adherence data during the 28 days evenly bracketing the clinic visit. Adherence within the implementation phase was measured using Medication Event Monitoring System (MEMS) caps. Wilcoxon tests were used to compare mean adherence between the following periods: Pre<jats:sub>14\u22124<\/jats:sub> (days 14 to 4 preceding the clinic visit) and Pre<jats:sub>3\u22121<\/jats:sub> (days 3 to 1 preceding the visit); Post<jats:sub>1\u22123<\/jats:sub> (days 1 to 3 following the clinic visit) and Post<jats:sub>4\u221214<\/jats:sub> (days 4 to 14 following the visit). Analyses were performed in the full sample and in patients with optimal (\u226580%, <jats:italic>n<\/jats:italic> = 49) and suboptimal adherence (&amp;lt;80%, <jats:italic>n<\/jats:italic> = 17).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-six patients were included, of which 51.5% were female. Mean age was 70.8 \u00b1 8.1 years. In the 6 months evenly bracketing the clinic visit, mean and median adherence were 86.3% (standard deviation = 17.7) and 95.6% (interquartile range = 21.2), respectively. Overall, mean adherence increased from Pre<jats:sub>14\u22124<\/jats:sub> to Pre<jats:sub>3\u22121<\/jats:sub> (85.5% \u00b1 21.2 to 88.5% \u00b1 23.2, <jats:italic>p<\/jats:italic> = 0.01) and decreased from Post<jats:sub>1\u22123<\/jats:sub> to Post<jats:sub>4\u221214<\/jats:sub> (87.0 \u00b1 23.9 to 84.9 \u00b1 23.3, <jats:italic>p<\/jats:italic> = 0.02). In patients with optimal adherence, adherence increased from Pre<jats:sub>14\u22124<\/jats:sub> to Pre<jats:sub>3\u22121<\/jats:sub> (94.0 \u00b1 11.7 to 97.7 \u00b1 7.4, <jats:italic>p<\/jats:italic> = 0.001) and from Post<jats:sub>1\u22123<\/jats:sub> to Post<jats:sub>4\u221214<\/jats:sub> (95.2 \u00b1 12.0 to 95.4 \u00b1 5.7, <jats:italic>p<\/jats:italic> = 0.007). Whitecoat adherence was not observed in patients with suboptimal adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We documented the presence of whitecoat adherence in this cohort. Due to its potential impact on clinical outcomes and decisions, providers should remain vigilant for this phenomenon and prioritize it during patient-provider discussions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.867884","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:16:43Z","timestamp":1652941003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Whitecoat Adherence in Patients With Primary Open-Angle Glaucoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Shervonne","family":"Poleon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouran","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyne","family":"Racette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham YC Li","year":"2014","journal-title":"Ophthalmology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Non-compliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1167\/iovs.07-0290","article-title":"Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma adherence and persistency study (GAPS)","volume":"48","author":"Friedman","year":"2007","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","article-title":"The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity","volume":"118","author":"Sleath","year":"2011","journal-title":"Ophthalmology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study","volume":"127","author":"Newman-Casey","year":"2020","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/0193945911427153","article-title":"Practical and analytic issues in the electronic assessment of adherence","volume":"34","author":"Cook","year":"2012","journal-title":"West J Nurs Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"P1161","DOI":"10.1002\/ppul.23138","article-title":"White coat adherence in children with asthma enrolled in a comprehensive asthma management program","volume":"44","author":"Keemink","year":"2014","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/1932296815623568","article-title":"White coat adherence in pediatric patients with type 1 diabetes who use insulin pumps","volume":"10","author":"Driscoll","year":"2016","journal-title":"J Diabetes Sci Technol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jpeds.2012.03.059","article-title":"White coat adherence over the first year of therapy in pediatric epilepsy","volume":"161","author":"Modi","year":"2012","journal-title":"J Pediat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e013496","DOI":"10.1136\/bmjopen-2016-013496","article-title":"ESPACOMP medication adherence reporting guidelines (EMERGE): a reactive-Delphi study protocol","volume":"7","author":"Helmy","year":"2017","journal-title":"BMJ Open."},{"key":"B11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12160-014-9641-8","article-title":"Predictors of adherence to glaucoma treatment in a multisite study","volume":"49","author":"Cook","year":"2015","journal-title":"Ann Behav Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08870446.2016.1244537","article-title":"Motivational interviewing or reminders for glaucoma medication adherence: results of a multi-site randomised controlled trial","volume":"32","author":"Cook","year":"2017","journal-title":"Psychol Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4103\/ijo.IJO_164_21","article-title":"Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India","volume":"69","author":"Subathra","year":"2021","journal-title":"Indian J Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ophtha.2021.10.009","article-title":"The impact of the coronavirus disease 2019 pandemic on adherence to ocular hypotensive medication in patients with primary open-angle glaucoma","volume":"129","author":"Racette","year":"2021","journal-title":"Ophthalmology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archophthalmol.2010.351","article-title":"Glaucoma medication adherence: room for improvement in both performance and measurement","volume":"129","author":"Muir","year":"2011","journal-title":"Arch Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1331\/JAPhA.2013.12065","article-title":"Medication adherence program: adherence challenges and interventions in type 2 diabetes","volume":"53","author":"Odegard","year":"2013","journal-title":"J Am Pharm Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jpsychores.2005.10.020","article-title":"The brief illness perception questionnaire","volume":"60","author":"Broadbent","year":"2006","journal-title":"J Psychosom Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"108392","DOI":"10.1016\/j.diabres.2020.108392","article-title":"White coat adherence effect on glucose control in adult individuals with diabetes","volume":"168","author":"Zueger","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","article-title":"Adherence with topical glaucoma medication monitored electronically: the travatan dosing aid study","volume":"116","author":"Okeke","year":"2009","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/IJG.0b013e31821dac86","article-title":"Determinants of medication adherence to topical glaucoma therapy","volume":"21","author":"Dreer","year":"2012","journal-title":"J Glaucoma."},{"key":"B22","doi-asserted-by":"publisher","first-page":"ofaa329","DOI":"10.1093\/ofid\/ofaa329","article-title":"PrEP Non-adherence, white coat dosing, and HIV risk among a cohort of MSM","volume":"7","author":"Blair","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0002-9394(86)90939-6","article-title":"Compliance with topical pilocarpine treatment","volume":"101","author":"Kass","year":"1986","journal-title":"Am J Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1755-3768.2012.02571.x","article-title":"Adherence improvement in Dutch glaucoma patients: a randomized controlled trial","volume":"91","author":"Beckers","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/eye.2010.27","article-title":"Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid","volume":"24","author":"Ajit","year":"2010","journal-title":"Eye."},{"key":"B26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/eye.2012.294","article-title":"Patterns of adherence behaviour for patients with glaucoma","volume":"27","author":"Cate","year":"2013","journal-title":"Eye."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ophtha.2015.06.039","article-title":"Patterns of glaucoma medication adherence over 4 years of follow-up","volume":"122","author":"Newman-Casey","year":"2015","journal-title":"Ophthalmology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"217047","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3122\/jabfm.2018.05.180009","article-title":"Medication adherence improvement similar for shared decision-making preference or longer patient-provider relationship","volume":"31","author":"Schoenthaler","year":"2018","journal-title":"J Am Board Family Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/OPX.0000000000001776","article-title":"Patient and provider perspectives on glaucoma treatment adherence: a delphi study in Urban Alabama","volume":"98","author":"Poleon","year":"2021","journal-title":"Optom Vis Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/IJG.0b013e31819c4679","article-title":"An exploratory study of factors influencing glaucoma treatment adherence","volume":"19","author":"Stryker","year":"2010","journal-title":"J Glaucoma."},{"key":"B32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3760\/cma.j.issn.0412-4081.2017.02.008","article-title":"Relationships among illness perceptions, medication beliefs and medication adherence in primary angle closure glaucoma patients","volume":"53","author":"Jiang","year":"2017","journal-title":"Zhonghua Yan Ke Za Zhi."},{"key":"B33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/bjo.2010.199851","article-title":"Validation of a short version of the glaucoma medication self-efficacy questionnaire","volume":"96","author":"Sleath","year":"2012","journal-title":"Br J Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2014.11.001","article-title":"Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence","volume":"122","author":"Sleath","year":"2015","journal-title":"Ophthalmology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.867884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:16:46Z","timestamp":1652941006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.867884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":34,"alternative-id":["10.3389\/fmed.2022.867884"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.867884","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"867884"}}